Protagonist Therapeutics (PTGX) Expected to Release Earnings on Thursday

Protagonist Therapeutics (NASDAQ:PTGX) is projected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of $2.50 per share and revenue of $238.49 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $2.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.27 by $0.02. The company had revenue of $213.47 million during the quarter, compared to analysts’ expectations of $212.03 million. Protagonist Therapeutics had a net margin of 29.40% and a return on equity of 12.03%. The firm’s quarterly revenue was up 3746.8% compared to the same quarter last year. On average, analysts expect Protagonist Therapeutics to post $4.59 EPS for the current fiscal year and $0.11 EPS for the next fiscal year.

Protagonist Therapeutics Stock Performance

Shares of PTGX opened at $140.24 on Wednesday. Protagonist Therapeutics has a one year low of $75.44 and a one year high of $160.81. The stock has a 50-day moving average price of $142.34 and a 200 day moving average price of $117.03. The company has a market capitalization of $9.07 billion, a P/E ratio of 135.31 and a beta of 1.21.

Wall Street Analysts Forecast Growth

PTGX has been the topic of several research analyst reports. The Goldman Sachs Group upgraded Protagonist Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $110.00 to $186.00 in a research note on Monday, August 10th. Truist Financial boosted their price objective on shares of Protagonist Therapeutics from $145.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, August 10th. TD Cowen increased their price objective on shares of Protagonist Therapeutics from $155.00 to $160.00 and gave the stock a “buy” rating in a research note on Wednesday, October 21st. Wall Street Zen cut shares of Protagonist Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 10th. Finally, UBS Group restated a “buy” rating on shares of Protagonist Therapeutics in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $163.27.

Insider Activity at Protagonist Therapeutics

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 65,761 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $149.11, for a total value of $9,805,622.71. Following the completion of the sale, the chief executive officer directly owned 523,478 shares in the company, valued at $78,055,804.58. This represents a 11.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Asif Ali sold 58,629 shares of the company’s stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $141.78, for a total value of $8,312,419.62. Following the completion of the sale, the chief financial officer owned 59,003 shares of the company’s stock, valued at $8,365,445.34. This trade represents a 49.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 283,629 shares of company stock valued at $41,443,786 over the last quarter. Insiders own 5.19% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc is a biopharmaceutical company focused on discovering and developing peptide-based medicines for immune-mediated and hematologic diseases. The company uses its proprietary peptide technology platform to design therapies intended to act on specific biological pathways and receptors.

Its leading program is icotrokinra, also known as JNJ-2113, an oral, targeted inhibitor of the interleukin-23 receptor being developed in collaboration with Janssen Pharmaceuticals for inflammatory and immune-mediated conditions, including psoriasis and inflammatory bowel diseases.